dic(9;12)(p13;p13) PAX5/ETV6 by Huret, Jean-Loup
Leukaemia Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(11) 409 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
dic(9;12)(p13;p13) PAX5/ETV6 
Jean-Loup Huret 
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, 
France; jean-loup.huret@chu-poitiers.fr 
Published in Atlas Database: January 2017 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/dic0912ID1065.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68998/01-2017-dic0912ID1065.pdf 
DOI: 10.4267/2042/68998
This article is an update of : 
dic(9;12)(p13;p13) PAX5/ETV6. Atlas Genet Cytogenet Oncol Haematol 2017;21(11) 
Strehl S. dic(9;12)(p13;p13) PAX5/ETV6. Atlas Genet Cytogenet Oncol Haematol 2004;8(2) 
Huret JL. dic(9;12)(p13;p13). Atlas Genet Cytogenet Oncol Haematol 2003;7(3) 
Huret JL. dic(9;12)(p11-13;p11-12). Atlas Genet Cytogenet Oncol Haematol 1997;1(1) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on dic(9;12)(p13;p13) PAX5/ETV6, with 
data on clinics and the genes involved. 
Keywords 
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Identity 
The fusion of PAX5 and ETV6 in the 
dic(9;12)(p13;p13) was first described by Strehl et 
al., 2003. PAX5/ETV6 fusion was found in 18/19 
(95%) dic(9;12) cases in a study by An et al., 2008, 
and one case was a dic(9;12)(p13;p12) with a 
PAX5/SLCO1B3 fusion. 
Clinics and pathology 
Disease 
dic(9;12)(p13;p13) is most often found in B cell 
acute lymphocytic leukemia (B-ALL), and very 
rarely in T-cell acute leukemia (T-ALL), chronic 
lymphocytic leukemia (CLL), or non Hodgkin 
lymphoma (NHL). 
Of 36 cases of dic(9;12) reviewed in Behrendt et al., 
1995, 31 were found in precursor acute  
lymphoblastic leukaemias (BCP-ALL), 2 in chronic 
myelogenous leukemia (CML) in blast crisis (BC-
CML), 1 in T-ALL, 1 in CLL, and 1 in NHL not 
otherwise specified. 
Phenotype/cell stem origin 
ALLs with dic(9;12) are most often L1/L2 and 
CD10+, at times CIg+ ALL. 
Epidemiology 
The PAX5 gene is altered by mutations, deletions or 
translocations in 30% of BCP-ALL patients and 
PAX5 chromosomal translocations account for 2-3% 
of cases (Cazzaniga et al., 2015).  
Dic (9;12) represents 1% of pediatric ALL (Behrendt 
et al., 1995) 
Plotting 32 cases of B-ALL cases reviewed in 
Behrendt et al., 1995 and the 36 cases published by 
An et al., 2008 (excluding the PAX5/ SLCO1B3 
case), median age was 12 years (range:1 yrs - 47 yrs; 
no infant case (< 1yr); 5 cases ≤ 2 yrs; 22 cases 
between ages 2 and 10; 14 cases above 18 yrs); 72% 
were male patients (sex ratio: 49M/19F). 
Clinics 
Moderate organomegaly. Blood data: moderate 
WBC. 
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dic(9;12)(p13;p13)  Top row: G- banding - Courtesy Jean-Luc Lai (left) and Diane H. Norback, Eric B. Johnson, Sara Morrison-
Delap UW Cytogenetic Services (middle left and middle); R- banding (right) with chr 12 up side down - Jean Loup Huret; 
Middle row: G- banding - Courtesy Jacqueline Van Den Akker (left) and Marilyn Slovak (middle left and middle); R- banding 
(right) with chromosome 12 up side down - Jacqueline Van Den Akker (middle right) and Jean Loup Huret (right); 
Bottom row: diagram and C-banding - Jean Loup Huret. 
 
 
 
 
 
 
Age at diagnosis in 32 cases of B-ALL and dic(9;12)(p13;p13) - Jean Loup Huret, unpublished information (cases studied in 
Behrendt et al., 1995). 
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White blood count, platelets count and Haemoglobin in 32 cases of B-ALL and dic(9;12)(p13;p13) - Jean Loup Huret, 
unpublished information (cases studied in Behrendt et al., 1995). 
 
Survival in 30 cases of B-ALL and dic(9;12)(p13;p13) - Jean Loup Huret, unpublished information (cases studied in Behrendt et 
al., 1995). One patient died at day 11 after diagnosis from cerebral hemorrhage during induction treatment (Huret et al., 1990); 
all other patients were alive and well at the times of publications. 
 
Treatment 
Bone marrow transplantation is not indicated, nor are 
high risk protocols in this leukemia with a fair 
prognosis. 
Prognosis 
Complete remission is obtained in all cases; 5 years 
survival > 95%. 
Cytogenetics 
Note 
The dicentric is formed with loss of parts of 9p and 
12p; therefore the ploidy is 45 chromosomes in cases 
where the dic(9;12) is the sole abnormality. 
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Cytogenetics morphological 
Of 68 cases (Behrendt et al., 1995; An et al., 2008) 
the dic(9;12) was the sole abnormality (at least 
within a sub-clone) in 28 cases (41%), and was 
accompanied with +8 (19 cases, 28%), +21 (4 cases), 
del(6q) (3 cases), or -5/del(5q) (2 cases). 
Genes involved and 
proteins 
PAX5/ETV6 fusion gene implicates two 
transcription factors, fundamental in hematopoiesis 
and in B cell development. 
PAX5 (paired box gene 5) 
Location 
9p13.2 
DNA/RNA 
The PAX5 coding region extends over a genomic 
interval of approximately 200kb and comprises 10 
exons. Two alternative transcripts have been 
identified, originating from alternative promotor 
usage, containing exon 1A or 1B. Full length mRNA 
is 3650 bp. 
Protein 
PAX5 belongs to the paired box family of 
transcription factors, involved in a multitude of 
developmental processes. PAX5 was originally 
identified as a B-cell specific transcription factor (B-
cell-specific activator protein, BSAP). Recently, it 
has been shown that PAX5 expression is not only 
continuously required for B cell lineage commitment 
during early B cell development but also for B 
lineage maintenance. Contains a paired box (DNA 
binding) domain, a truncated homeo domain 
homology region, a transactivation domain, and an 
inhibitory domain. 
ETV6 (ets variant 6) 
Location 
12p13.2 
DNA/RNA 
Alternative transcripts. 
Protein 
Contains a HLH domain, also referred to as the 
pointed or sterile alpha motif domain, responsible for 
hetero- and homodimerization, and a ETS-DNA 
binding domain, responsible for sequence specific 
DNA-binding and protein-protein interaction; ETV6 
is an ETS-related transcription factor, transcriptional 
repressor that binds to DNA sequence 5'- 
CCGGAAGT-3', It can form homodimers or 
heterodimers with ETV7 or FLI1. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
In a study of dic(7;9) (n= 13), dic(9;12) (n=38), and 
dic(9;20) (n=59), breakpoints on 9p were found to be 
heterogeneous; however, all breakpoints resulted in 
loss of a large number of genes on 9p, including the 
tumor suppressor gene, CDKN2A (An et al., 2008).  
5'PAX5 / 3'ETV6 transcript, no reciprocal transcript 
due to deletion  
In the dic(9;12) cases, the breakpoints were located 
within intron 4 of PAX5 in 8 of 8 cases, whereas 7 
were intron 2 and 1 in intron 1 of ETV6 (An et al., 
2008). 
Detection 
RT-PCR, FISH. 
Fusion protein 
Description 
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The PAX5/ETV6 chimeric transcript results in 
fusion of the paired box domain (PRD) of PAX5 
(DNA binding domain of PAX5) to the helix-loop-
helix and ETS-binding domains of ETV6 (DNA 
binding, dimerization and transcription regulation 
domains of ETV6).  
Of note: the putative chimeric protein contains the 
DNA-binding domains of both fusion partners, 
namely the PRD and the ETS-domain. 
Expression / Localisation 
PAX5/ETV6 localizes in the nucleus and the 
cytoplasm. 
Oncogenesis 
PAX5/ETV6 acts as a transcriptional repressor. 
PAX5/ETV6 can multimerize and bind the PAX5-
consensus sequence, determining a dominant 
negative activity on wild type PAX5. PAX5/ETV6 
represses 56% and activates 44% of PAX5-target 
genes, respectively in the study by Fazio et al., 2013.  
On the other hand, only a few ETV6 transcriptional 
target genes were differentially expressed. 
PAX5/ETV6 determines a PAX5 haplo-
insufficiency setting; the PAX5/ETV6 fusion protein 
could be actively responsible for the B-cell 
development block, mediated by the repression of 
physiological PAX5-activated genes (Fazio et al., 
2013). 
PAX5-ETV6 also interacted with wild-type ETV6, 
supporting the notion that the ETV6 sterile alpha 
domain mediates oligomerization of ETV6 and 
ETV6 fusion proteins (Fortschegger et al., 2014). 
LCK is up-regulated by PAX5/ETV6. LCK hyper-
activation, and down-regulation of its negative 
regulator CSK, lead to STAT5 over-phosphorylation 
and hyper-activation and to up-regulation of the 
downstream effectors, MYC and CCND2.  
Hyper-activation of STAT5 pathway can represent a 
survival signal in PAX5 translocated cells 
(Cazzaniga et al., 2015). 
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